Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for 10x Genomics, Inc. (NASDAQ: TXG), a life science technology company specializing in single cell and spatial biology. Through these filings, investors and researchers can review the company’s regulatory disclosures, including annual and quarterly reports and current reports on material events.
10x Genomics’ Class A common stock is registered on The Nasdaq Stock Market LLC under the symbol TXG, as noted in its Form 8-K filings. The company uses SEC filings, along with its website, press releases, public conference calls, webcasts and social media accounts, as channels for disclosing information and for complying with Regulation FD. Form 8-K filings have addressed topics such as quarterly financial results and changes in certain executive roles.
Key SEC documents for TXG include annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed information about revenue by product type and geography, gross margin, operating expenses, cash and marketable securities, and risk factors. Current reports on Form 8-K provide timely updates on specific events, such as earnings releases or leadership changes. Together, these filings give a structured view of how 10x Genomics’ single cell and spatial biology business is performing and evolving.
On Stock Titan, users can view TXG filings as they are made available from EDGAR and use AI-powered summaries to interpret complex sections, such as revenue breakdowns, operating results and risk disclosures. Filings related to topics like license and royalty revenue, services, and geographic revenue distribution can be examined to understand the company’s financial profile. This page also offers convenient access to insider and governance-related filings, helping users track corporate developments over time.
10x Genomics, Inc. director Sarah A. Teichmann reported an open-market sale of 7,579 shares of Class A Common Stock at $19.41 per share. After this transaction, she directly holds 26,780 shares. The sale was executed under her pre-arranged Rule 10b5-1 trading plan.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported an open-market sale of 9,632 shares of Class A common stock on February 23, 2026 at an average price of $18.5764 per share. The shares were sold to cover tax withholding obligations related to vesting restricted stock units.
After this transaction, Saxonov directly held 1,061,924 Class A shares. In addition, indirect holdings as trustee included 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust.
10x Genomics Chief Financial Officer Adam Taich reported an open-market sale of 8,968 shares of Class A Common Stock. The transaction took place on February 23, 2026 at an average price of $18.5764 per share, and was conducted to cover tax withholding obligations related to vesting restricted stock units.
After this transaction, Taich directly owned 288,417 shares of 10x Genomics Class A Common Stock.
10x Genomics, Inc. director and officer Benjamin J. Hindson reported an open-market sale of 7,826 shares of Class A common stock at an average price of $18.5764 per share. According to the filing, the shares were sold to cover tax withholding obligations from vesting restricted stock units. After this transaction, Hindson directly owns 424,779 shares.
TXG filed a Form 144 reporting a proposed sale of common stock by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists restricted stock lots of 3,740 shares dated 11/21/2025 and 3,839 shares dated 08/21/2025.
Benjamin J. Hindson submitted a Form 144 reporting a proposed sale of 8,301 shares of common stock, listed with Morgan Stanley Smith Barney LLC and dated 02/23/2026. The filing also records a prior sale of 8,283 shares on 11/24/2025. The securities to be sold reference a Restricted Stock Unit Grant dated 02/21/2026.
TXG files a Form 144 disclosing an intended sale of 25,784 shares of Common Stock tied to a Restricted Stock Unit Grant dated 02/21/2026. The notice also reports an earlier sale of 13,261 shares on 11/24/2025 for $251,936.46.
TXG files a Form 144 reporting a proposed sale of Common Stock. The notice lists 23,767 shares associated with a Restricted Stock Unit grant dated 02/21/2026. The filing also discloses an earlier sale of 11,888 shares on 11/24/2025 by Adam Taich.
10x Genomics, Inc. is a life sciences technology company focused on single cell, spatial and in situ analysis through its Chromium, Visium and Xenium platforms, supported by software like Cell Ranger, Loupe Browser and Xenium Explorer. In 2025 it acquired Scale Biosciences, adding QuantumScale single cell kits.
For the year ended December 31, 2025, revenue was $642.8 million, up 5% from $610.8 million in 2024, while net loss narrowed to $43.5 million from $182.6 million. The company sold 1,007 instruments and 424,000 consumable reactions in 2025 and estimates a total addressable market above $21 billion. Key risks include dependence on academic and government research funding (notably NIH), intense competition in genomics tools, potential pricing pressure, trade and tariff exposure, and execution challenges in entering clinical and diagnostic markets.
10x Genomics reported modest revenue growth but sharply improved profitability for 2025. Revenue was $166.0 million in Q4 2025, up 1% year over year, with full-year revenue of $642.8 million, a 5% increase from 2024. Excluding $44.1 million of non-recurring patent litigation settlement revenue, full-year revenue was $598.7 million, a 2% decline.
Q4 gross margin improved to 68% and full-year gross margin to 69%. Operating expenses fell 18% in Q4 and 17% for the year, helped by lower legal and personnel costs and a $49.9 million litigation settlement gain. Net loss narrowed to $16.3 million in Q4 2025 from $49.0 million a year earlier, and to $43.5 million for 2025 from $182.6 million in 2024.
The company ended 2025 with $523.4 million in cash, cash equivalents and marketable securities. For 2026, 10x Genomics guides to revenue of $600–$625 million, which represents 0% to 4% growth versus 2025 after excluding non-recurring patent-related revenue.